Application of anoectochilus formosanus polysaccharide in preparation of medicine for resisting ulcerative colitis

Through the extraction and purification of the auricular polysaccharide, the problem of high toxicity and recurrence rate of ulcerative colitis is solved, and a safe and effective treatment plan is provided, which significantly improves the disease activity index and intestinal inflammation in mice.

CN119055677APending Publication Date: 2024-12-03FUJIAN UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202411286022.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-13
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing treatment drugs for ulcerative colitis have serious adverse reactions such as cardiotoxicity, liver and kidney toxicity, and have a high recurrence rate, and lack efficient and low-toxic prevention and treatment drugs.

Method used

The use of nigra polysaccharides, including crude polysaccharide ARP and homogeneous polysaccharide ARP-1a, was prepared by specific extraction and purification methods for the prevention and treatment of ulcerative colitis, significantly improving the mice's disease activity index and intestinal inflammation.

Benefits of technology

The polysaccharide of the genus saccharide significantly prevents ulcerative colitis, reduces colon shortening, inhibits intestinal inflammation, relieves intestinal pathological damage, provides safe and effective treatment plans, and the preparation method is simple and efficient.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055677A_ABST
    Figure CN119055677A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of traditional Chinese medicines, and relates to a novel pharmaceutical application of anoectochilus roxburghii polysaccharide, in particular to an application of anoectochilus roxburghii crude polysaccharide (ARP) and homogeneous polysaccharide ARP-1a in preparation of medicines for preventing and treating ulcerative colitis. The anoectochilus formosanus crude polysaccharide extract (ARP) and the homogeneous polysaccharide ARP-1a are extracted and separated from the traditional Chinese medicine anoectochilus formosanus, and animal experiments prove that the anoectochilus formosanus crude polysaccharide extract (ARP) and the homogeneous polysaccharide ARP-1a have a remarkable prevention effect on mouse ulcerative colitis induced by 3% DSS. The total anoectochilus roxburghii polysaccharide (ARP) and the homogeneous anoectochilus roxburghii polysaccharide ARP-1a can reduce secretion of inflammatory cytokines TNF-alpha, IL-1beta and IL-6 and promote secretion of an anti-inflammatory factor IL-10 by inhibiting infiltration of inflammatory cells in colon, so that mouse colon lesion is reduced, intestinal function completeness is protected, and weight loss and colon length shortening caused by DSS are slowed down. The compound can be used for preparing medicines for preventing and treating ulcerative colitis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of pharmaceuticals and relates to the use of roxburghii polysaccharide in preparing medicines for preventing and treating ulcerative colitis. Background Art

[0002] Ulcerative colitis (UC) is a chronic nonspecific intestinal inflammatory disease of unknown cause. Its incidence rate is increasing year by year and has become an important public health problem worldwide. There is currently no specific drug to cure UC. Common methods of Western medicine treatment for UC include administration of aminosalicylic acid preparations, glucocorticoids, and immunosuppressants. 5-aminosalicylic acid has always been the first-line drug for the treatment of ulcerative colitis, but its adverse reactions of cardiotoxicity and hepatorenal toxicity cannot be ignored; for mild patients who are ineffective with 5-aminosalicylic acid, glucocorticoid drugs are often chosen, but while they exert strong immunosuppression, they also cause serious adverse reactions such as osteoporosis and diabetes, increasing the mortality rate. Immunosuppressants are commonly used to maintain remission in patients with colitis, but immunosuppressants take a long time to take effect, have certain cytotoxicity, and long-term use can also cause liver and kidney damage. Although the current drugs for the treatment of UC can quickly relieve symptoms, they have a high recurrence rate and are prone to serious adverse reactions when used for a long time. Therefore, seeking highly effective and low-toxic drugs for the prevention and treatment of UC is still an arduous task and problem facing the world medical community.

[0003] Anoectochilus roxburghii is one of the traditional Chinese medicines of Fujian Province, which is derived from the plant Anoectochilus roxburghii of the Orchidaceae family. Anoectochilus roxburghii (Wall.) Lindl. The whole plant has the effects of clearing away heat and detoxifying, cooling blood, dispelling wind and dampness. In recent years, the high medicinal and health value of Anoectochilus roxburghii has attracted the attention and research of many scholars at home and abroad. Many studies have shown that polysaccharides are one of the main active ingredients of Anoectochilus roxburghii, accounting for about 10% of the raw medicinal amount of Anoectochilus roxburghii, and have multiple biological activities such as anti-inflammatory, antioxidant, liver protection, and hypoglycemic. Studies have shown that the relative molecular mass of A. roxburghii uniform polysaccharide ARP-1a is M 1.47×10 4Da, the monosaccharide composition is composed of mannose, glucose and galactose (molar ratio is 1:13.24:1.69), which has a significant hepatoprotective effect (Yanbin Wu, Xuhui He, Huiling Chen, et al. Extraction and characterization of hepatoprotective polysaccharides from Anoectochilus roxburghii against CCl4-induced liver injury via regulating lipid metabolismand the gutmicrobiota, International Journal of Biological Macromolecules,2024, 277: 134305). So far, there has been no report on the prevention and treatment of ulcerative colitis by Anoectochilus polysaccharides. Summary of the invention

[0004] The technical problem to be solved by the present invention is to provide the use of roxburghii polysaccharide in preparing a medicine for preventing and treating ulcerative colitis in view of the deficiencies in the prior art.

[0005] In order to solve the above technical problems, the present invention discloses the use of roxburghii polysaccharide in preparing a medicine for preventing and treating ulcerative colitis.

[0006] Preferably, the roxburghii roxburghii polysaccharide includes roxburghii roxburghii crude polysaccharide ARP and roxburghii roxburghii homogeneous polysaccharide ARP-1a.

[0007] Preferably, the preparation method of the crude polysaccharide ARP of Anoectochilus roxburghii comprises the following steps: placing fresh Anoectochilus roxburghii in an oven and drying at 60 ºC, adding 30 times by weight of a 95% ethanol solution by volume concentration, refluxing and extracting twice, 2 h / time; filtering, adding 30 times by weight of pure water to the residue and refluxing and extracting three times, 2 h / time; mixing the extracted water extracts, filtering, concentrating, adding anhydrous ethanol to a volume concentration of 80% ethanol, standing at 4°C for 12 h, filtering, evaporating the ethanol, re-dissolving the precipitate with pure water, dialyzing with a dialysis bag with a molecular weight cutoff of 3500 Da for 48 h, and freeze-drying to obtain the crude polysaccharide ARP of Anoectochilus roxburghii.

[0008] Preferably, the preparation method of the uniform polysaccharide ARP-1a of Anoectochilus roxburghii comprises the following steps: passing the crude polysaccharide ARP of Anoectochilus roxburghii through a DEAE Sepharose Fast Flow ion exchange chromatography column, gradient eluting with pure water, 0.2 and 0.4 mol / L NaCl solutions in sequence, purifying the pure water elution portion with a Sephacryl S-200 gel column to obtain the uniform polysaccharide ARP-1a of Anoectochilus roxburghii.

[0009] The repeating structural unit of the homogeneous polysaccharide ARP-1a of Anoectochilus roxburghii is as follows: The experimental results of the present invention show that the above-mentioned crude polysaccharide of Anoectochilus roxburghii and uniform polysaccharide ARP-1a have a significant preventive effect on ulcerative colitis in mice induced by dextran sulfate sodium (DSS), can significantly improve the disease activity index of ulcerative colitis mice, reduce the shortening of the mouse colon, inhibit the occurrence of intestinal inflammation, and alleviate intestinal pathological damage.

[0010] The advantages of the present invention are: (1) The present invention provides a safe and effective therapeutic drug for the clinical treatment of ulcerative colitis, a difficult-to-treat disease, and has a wide range of clinical applications. The preparation method is simple and efficient, and the extracted roxburghii polysaccharide is easy to carry and convenient to take.

[0011] (2) Advanced research methods: The experiment of the present invention recorded the changes in mouse weight, colon length, and bloody stools. HE staining, AB-PAS staining and other methods were used to confirm intestinal inflammation and intestinal pathological structure as well as the improvement after drug treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] The present invention will be further described below in conjunction with the accompanying drawings and specific embodiments, and the advantages of the present invention will become more clear.

[0013] Figure 1 is the DAI score of mice according to one embodiment of the present invention (n=6); Figure 2 is the length of mouse colon according to one embodiment of the present invention (n=6), Note: Compared with the DSS group, ** express P <0.01, * express P <0.05; compared with the normal group, ## express P <0.01, # P <0.05; Figure 3 This is a HE staining image of mouse colon tissue according to one embodiment of the present invention (100×), Note: A: normal group, B: DSS group, C: Mes group, D: ARP-H group, E: ARP-M group, F: ARP-L group, G: ARP-1a-H group, H: ARP-1a-M group, I: ARP-1a-L group; Figure 4This is an AB-PAS staining image of mouse colon tissue according to one embodiment of the present invention (100×), Note: A: normal group, B: DSS group, C: Mes group, D: ARP-H group, E: ARP-M group, F: ARP-L group, G: ARP-1a-H group, H: ARP-1a-M group, I: ARP-1a-L group; Figure 5 The levels of inflammatory cytokines in the colon tissue of mice according to one embodiment of the present invention (n=6), A: TNF-α, B: IL-1β, C: IL-6, D: IL-10; Note: Compared with the DSS group, ** express P <0.01, * express P <0.05; compared with the normal group, ## express P <0.01, # P <0.05. DETAILED DESCRIPTION

[0014] In order to make the above features and advantages of the present invention more clearly understood, the following embodiments are given for detailed description. The methods of the present invention are all conventional methods in the art unless otherwise specified.

[0015] Example 1: Preparation of Anoectochilus roxburghii polysaccharide Fresh Anoectochilus roxburghii was placed in an oven and dried at 60 ºC. Then, 30 times the weight of 95% ethanol solution was added and refluxed at 80 ºC for 2 times, 2 h / time. Filter, add 30 times the weight of pure water to the residue and refluxed at 90 ºC for 3 times, 2 h / time. The extracted water extract was mixed, filtered, concentrated to a certain volume, anhydrous ethanol was added until the ethanol volume concentration reached 80%, and the mixture was allowed to stand at 4 ℃ for 12 h, filtered, the ethanol was evaporated, the precipitate was re-dissolved in pure water, dialyzed with a dialysis bag with a molecular weight cutoff of 3500 Da for 48 h, and freeze-dried to obtain Anoectochilus roxburghii crude polysaccharide (ARP). ARP was passed through a DEAE Sepharose Fast Flow ion exchange chromatography column, and gradient eluted with pure water, 0.2 and 0.4 mol / L NaCl solutions in sequence. The pure water elution portion was purified with a Sephacryl S-200 gel column to obtain Anoectochilus roxburghii uniform polysaccharide ARP-1a.

[0016] Example 2: Pharmacological efficacy test of Anoectochilus roxburghii polysaccharide against ulcerative colitis A total of 54 C57BL / 6 mice were randomly divided into 9 groups according to the random number principle after 5 days of adaptive feeding: normal control group; model group (3%DSS group); mesalazine group (Mes group); high-dose Aromatic Thread Polysaccharide group (ARP-H group); medium-dose Aromatic Thread Polysaccharide group (ARP-M group); low-dose Aromatic Thread Polysaccharide group (ARP-L group); high-dose Aromatic Thread Polysaccharide (ARP-1a-H group); medium-dose Aromatic Thread Polysaccharide (ARP-1a-M group); low-dose Aromatic Thread Polysaccharide (ARP-1a-L group); 6 mice in each group were given the drug once a day. The normal control group and the model group were gavaged with 0.1 mL / 10 g normal saline for 15 days. The ARP-H group and ARP-1a-H group were gavaged with 120 mg / kg; the ARP-M group and ARP-1a-M group were gavaged with 60 mg / kg dose; ARP-L group and ARP-1a-L group were gavaged at a dose of 30 mg / kg, and Mes group was gavaged at a dose of 200 mg / kg. Except for the normal group, mice in other groups were allowed to drink 3% DSS solution prepared on the same day for 8 days from the eighth day of gavage to establish the mouse ulcerative colitis model. The blank group was allowed to drink pure water freely and fasted but not water within 12 h after the last administration. The mice after modeling were weighed and weighed continuously for 8 days. The feces of the mice were observed using OB test paper and the disease activity index (DAI) score of the mice was recorded. After the experiment, the mouse serum was obtained by eye blood sampling and centrifuged at 4 500 r / min for 15 min to obtain the serum. Then, part of the mouse colon tissue was quickly removed and the colon length was measured. Part of the colon tissue was fixed in 4% paraformaldehyde solution, and the remaining colon tissue was stored in a -80℃ refrigerator for other index detection. The levels of TNF-α, IL-1β, IL-6, and IL-10 in mouse serum were determined according to the instructions of the kit; liver tissues of mice were taken and the levels of liver malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH) were determined according to the instructions of the kit; part of the colon tissue was fixed in 4% paraformaldehyde, dehydrated, paraffin-embedded, sectioned, and stained with hematoxylin-eosin (HE) and AB-PAS, and the pathological changes of colon tissues of mice in each group were observed under a microscope.

[0017] like Figure 1As shown in the figure, the DAI score of mice in the normal group basically remained at around 0, the DSS group showed a steady increase, and compared with the DSS group, the drug-treated group also basically showed an upward trend, but the increase was much smaller than that of the DSS group, among which the ARP-H group had the smallest increase. On the seventh day of drinking 3% DSS, the DAI of the model group increased compared with the normal group; and compared with the model group, the DAI scores of the ARP and ARP-1a drug-treated groups at each dose were lower than those of the model group. This shows that the total polysaccharide ARP and the uniform polysaccharide ARP-1a of golden thread vine have an improvement effect on the weight loss and bloody stool of colitis mice.

[0018] like Figure 2 As shown in Figure 2, compared with the normal control group, the colon length of mice in the DSS group was significantly shortened ( P <0.01); however, after ARP and ARP-1a intervention, the ARP group and ARP-1a dose groups could significantly improve the shortening of colon length caused by DSS ( P <0.01), there was no significant difference in ARP and ARP-1a among the treatment groups.

[0019] Comprehensive HE staining ( Figure 3 ) and AB-PAS stained sections ( Figure 4 ) The results showed that the colon epithelium of mice in the normal group was intact, the glands were neatly arranged, and there was no inflammatory cell infiltration; after DSS treatment, the colon epithelium of mice in the DSS group was severely desquamated, the mucosal layer was infiltrated with a large number of inflammatory cells, the crypts were completely atrophied and twisted, and a large number of goblet cells were missing; compared with the colon tissue of mice in the DSS group, the ARP and ARP-1a groups could improve the abnormal colon crypt structure caused by DSS, and the degree of improvement varied slightly with the different drug concentrations. Although the crypt structure of the ARP-1a-H group was distorted, its The colonic crypts were arranged neatly; the improvement degree of the ARP-1a-M group was similar to that of the ARP-1a-H group, but the crypt structure showed branches, and there was also inflammatory cell infiltration; the mucosal layer of the ARP-1a-L group showed obvious inflammatory cell infiltration, the crypt structure was partially lost, and the goblet cells increased compared with the DSS group; the crypt structure of the ARP-H group was partially intact, and the goblet cells increased; the crypts of the ARP-M group were distorted, the inflammatory cell infiltration was more obvious, but the crypt structure was complete; the crypt structure of the ARP-L group was partially intact, with inflammatory cell infiltration and serious goblet cell loss. In summary, the ARP-1a treatment groups had better improvements in the colonic crypt structure and goblet cell loss than ARP, among which the ARP-1a-H group had the best improvement effect.

[0020] The levels of inflammatory factors in the colon tissue of mice Figure 5As shown in Figure 2, compared with the normal group, the levels of proinflammatory cytokines TNF-α, IL-1β, and IL-6 in the colon tissue of mice in the DSS group were significantly increased ( P <0.01), the level of anti-inflammatory cytokines was significantly reduced ( P <0.01); after intragastric administration of ARP and ARP-1a, the levels of pro-inflammatory factors were significantly reduced ( P <0.01), the level of anti-inflammatory factors increased significantly ( P <0.01). Among them, both ARP and ARP-1a administration groups can reduce the level of pro-inflammatory cytokines and increase the level of anti-inflammatory cytokines in a dose-dependent manner, and the efficacy is stronger with the increase of dose. The ARP-1a-H group has a better effect on the improvement of inflammatory factor levels in colon tissue than ARP-H, which is equivalent to mesalazine.

[0021] The above description is only a preferred embodiment of the present invention. All equivalent changes and modifications made according to the scope of the patent application of the present invention should fall within the scope of the present invention.

Claims

1. The use of Anoectochilus roxburghii polysaccharide in the preparation of anti-ulcerative colitis drugs, characterized in that: The roxburghii roxburghii polysaccharide includes roxburghii roxburghii crude polysaccharide ARP and roxburghii roxburghii uniform polysaccharide ARP-1a.

2. The use according to claim 1, characterized in that: The preparation method of the crude polysaccharide ARP of roxburghii comprises the following steps: placing fresh roxburghii in an oven at 60°C for drying, adding 30 times by weight of a 95% ethanol solution in volume concentration, refluxing and extracting for 2 times, 2 hours per time; filtering, adding 30 times by weight of pure water to the residues for reflux extraction for 3 times, 2 hours per time; mixing the extracted water extracts, filtering, concentrating, adding anhydrous ethanol until the ethanol volume concentration reaches 80%, standing at 4°C for 12 hours, filtering, evaporating the ethanol, re-dissolving the precipitate in pure water, dialyzing for 48 hours with a dialysis bag with a molecular weight cutoff of 3500 Da, and freeze-drying to obtain the crude polysaccharide ARP of roxburghii.

3. The use according to claim 1, characterized in that: The preparation method of the uniform polysaccharide ARP-1a of roxburghii roxburghii comprises the following steps: passing the crude polysaccharide ARP of roxburghii roxburghii through a DEAE Sepharose Fast Flow ion exchange chromatography column, gradient eluting with pure water, 0.2 mol / L NaCl solution and 0.4 mol / L NaCl solution in sequence, purifying the pure water elution part with a Sephacryl S-200 gel column to obtain the uniform polysaccharide ARP-1a of roxburghii roxburghii.

Citation Information

Cited By

  • Anoectochilus roxburghii polysaccharide and application thereof in preparation of cartilage injury repair medicine

    CN119350524A

  • Extraction method and application of anoectochilus formosanus exosome

    CN120713980A

  • Extraction method and application of ananas comosus exosome

    CN120713980B